<DOC>
	<DOCNO>NCT00001680</DOCNO>
	<brief_summary>The purpose double-masked , pilot trial determine whether 20 percent thalidomide ointment safe effective treatment chronic discoid lupus erythematosus ( CDLE ) use occlusive dressing . Seventeen patient two similar lesion lesion randomize receive either intervention placebo therapy .</brief_summary>
	<brief_title>A Pilot Trial Topical Thalidomide Management Chronic Discoid Lupus Erythematosus</brief_title>
	<detailed_description>The purpose double-masked , pilot trial determine whether 20 % thalidomide ointment safe effective treatment chronic discoid lupus erythematosus ( CDLE ) use occlusive dressing . Seventeen patient two similar lesion lesion randomize receive either intervention placebo therapy .</detailed_description>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Lupus Erythematosus , Discoid</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Age , 18 . Must lesion fulfill clinical histologic criterion active CDLE . Lesions must least 3 month duration must treat topical steroid retinoids least 3 week . Patient must least two similar lesion accommodate 2X3 inch dress . Patient must willing two 4 mm biopsy prior onset therapy four 4 mm biopsy end study period . In absence systemic involvement , CDLE lesion must respond least 3 month therapy topical steroid , sunscreen without antimalarial hydroxychloroquine . If CDLE present association systemic involvement , lesion must respond 3 month stable conventional systemic therapy and/or topical steroid sunscreen . If female , patient must negative pregnancy test prior study entry . If female , must postmenopausal surgically sterile , sexually inactive , practice successful contraception two method birth control simultaneously least one month prior start thalidomide continue use another month last application thalidomide . If male , patient must surgically sterilize , sexually inactive , use condom study continue regular use one month last application thalidomide . Patients must normal cognitive ability able understand experimental nature therapy , able follow instruction regard application medication correct use contraceptive measure . Patients must pregnant lactating . Patients must renal disease ( serum creatinine great 2 time upper limit normal . Patients must hepatic dysfunction ( liver function test great 2 time upper limit normal ) . Patients must unstable systemic lupus erythematosus systemic therapy maintain steady dos duration study . Patients must use topical steroid duration study . Patients must currently receive systemic thalidomide . Patients must hypersensitive thalidomide . Patients must presence polyneuropathy ( objective sensory loss motor weakness reflex loss ) exception focal nerve entrapment syndrome ( carpal tunnel syndrome ) , receive drug know suspected neuropathic side effect . Patients must condition therapy opinion investigator may pose risk patient confound result study .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2000</verification_date>
	<keyword>Double-masked</keyword>
	<keyword>Neuropathy</keyword>
	<keyword>Occlusive Dressing</keyword>
	<keyword>Pilot</keyword>
	<keyword>Placebo</keyword>
</DOC>